文献速递浆细胞疾病

多发性骨髓瘤新型骨修饰治疗应用的争议

Controversies in the use of new bone-modifying therapies in multiple myeloma.
PubMed 文献 · Br J Haematol · 2020-11-29

本文综述多发性骨髓瘤骨修饰治疗的争议点,包括唑来膦酸与地舒单抗的选择、停药时机及COVID-19期间给药策略。地舒单抗在预防骨骼相关事件方面非劣于双膦酸盐,可能对适合自体移植患者有生存获益,且肾损伤患者安全性更佳;停药需警惕反弹效应。

要点

  • 唑来膦酸因减少骨骼相关事件和改善生存优于其他双膦酸盐。
  • 地舒单抗预防骨骼相关事件非劣于双膦酸盐,肾损伤患者更安全。
  • 深度缓解且充分治疗后考虑停药,地舒单抗需警惕反弹效应。

核心结论

  • 骨修饰治疗是多发性骨髓瘤治疗的重要组成部分,新型药物应用存在争议。

主要发现

  • 唑来膦酸在减少骨骼相关事件发生率和改善生存方面优于其他双膦酸盐。
  • 地舒单抗在初诊骨髓瘤骨病患者中预防骨骼相关事件非劣于双膦酸盐。
  • 地舒单抗可能为适合自体移植的患者带来生存获益。
  • 地舒单抗可能为肾损伤患者提供更安全的特性。
  • 深度缓解且经过适当治疗时间后可考虑停用骨靶向治疗,但地舒单抗可能出现反弹效应。

关键数值与推荐

  • COVID-19大流行期间应考虑唑来膦酸每3个月输注一次或地舒单抗居家给药。
  • 所有骨修饰药物均需重视预防低钙血症、肾毒性和颌骨坏死。

临床怎么用

  • 根据患者肾功能、移植 eligibility 及疫情背景个体化选择骨修饰药物。
  • 深度缓解患者可考虑停药,但地舒单抗停药需监测反弹效应。
  • 所有使用骨修饰药物的患者均应采取预防低钙血症、肾毒性和颌骨坏死的措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone-modifying therapies are essential in the treatment of patients with multiple myeloma. Zoledronic acid is preferred over other bisphosphonates due to its superiority in reducing the incidence of skeletal-related events and improving survival. The anti-receptor activator of nuclear factor-κΒ ligand (RANKL)-targeted agent denosumab has shown its non-inferiority compared to bisphosphonates in preventing skeletal-related events among newly diagnosed patients with myeloma bone disease. Denosumab may confer a survival benefit in patients eligible for autologous transplantation. Denosumab may present a safer profile for patients with renal impairment. Discontinuation of bone-directed therapies can be considered for patients with deep responses and after an adequate time period on treatment; however, a rebound effect may become evident especially in the case of denosumab. Three-monthly infusions of zoledronic acid or at-home denosumab administration should be considered during the coronavirus disease 2019 (COVID-19) pandemic. Measures to prevent hypocalcaemia, renal toxicity and osteonecrosis of the jaw are important for all bone-modifying agents.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Ntanasis-Stathopoulos I. Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2020. PMID: 33249579. doi:10.1111/bjh.17256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。